Skip to main content

Table 4 Associations between presence of IgG antibodies to GLURP-R0 + R2 and parasite haplotypes in relation to treatment outcome.

From: Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum

   GLURP-R0 GLURP-R2
Treatment and group SP Presence of antibody/resistant haplotype* TF ACPR TF ACPR
1 +/- 2 4 1 6
2 -/- 4 3 5 2
3 +/+ 6 7 9 7
4 -/+ 22 2 19 1
AQ      
1 +/- 1 7 0 8
2 -/- 2 5 3 4
3 +/+ 4 12 3 11
4 -/+ 12 6 13 7
  1. TF: Parasitological or clinical treatment failure, ACPR: Adequate clinical and parasitological response. SP: sulphadoxine-pyrimethamine, AQ: amodiaquine. *Number of patients with presence (+) or absence (-) of IgG antibodies to GLURP-R0 or R2 combined with resistant (+) or sensitive (-) genotypes associated with treatment outcome. Haplotypes were defined as resistant if parasites expressed the dhfr triple haplotype (CIRN) for the SP group or the CVIET haplotype for the AQ group.